Primary Sclerosing Cholangitis
Gastroenterology·MeSH: Cholangitis, Sclerosing
Prevalence
5.0 / 100K
7 drugs in development·5 companies·8 clinical trials
Drug Pipeline by Phase
Phase 2(3)
Phase 1(1)
| Drug | Company |
|---|---|
| aramchol | Galmed Pharmaceuticals Ltd. (GLMD) |
Preclinical(1)
| Drug | Company |
|---|---|
| IRF5 program | ALUMIS INC. (ALMS) |
Early Phase 1(1)
| Drug | Company |
|---|---|
| Rosuvastatin | Valneva SE (VALN) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| aldafermin | NGM BIOPHARMACEUTICALS INC (NGM) |
Compare drugs
Frequently asked questions
How many drugs are in development for Primary Sclerosing Cholangitis?
BioSniper tracks 7 drugs in development for Primary Sclerosing Cholangitis across 5 companies.
How many clinical trials target Primary Sclerosing Cholangitis?
There are 8 clinical trials targeting Primary Sclerosing Cholangitis tracked by BioSniper.
What is the prevalence of Primary Sclerosing Cholangitis?
The estimated prevalence of Primary Sclerosing Cholangitis is approximately 5.0 per 100,000 population.
Deep-dive into Primary Sclerosing Cholangitis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis